Comparative studies of glial fibrillary acidic protein and brain-derived neurotrophic factor expression in two transgenic mouse models of Alzheimer's disease.

Comparative studies of glial fibrillary acidic protein and brain-derived neurotrophic factor expression in two transgenic mouse models of Alzheimer's disease. Clin Exp Pharmacol Physiol. 2020 Jun 16;: Authors: Edwards SR, Khan N, Coulson EJ, Smith MT Abstract In Alzheimer's disease (AD)glial fibrillary acidic protein (GFAP) is expressed by reactive astrocytessurroundingβ-amyloid (Aβ) plaques, whereasbrain-derived neurotrophic factor (BDNF) levels are typically reduced. We compared the expression of GFAP, BDNF, and its precursor proBDNF in the dorsal hippocampus of two transgenicAD mouse models.APPSwe YAC mice expressing the APPSwe transgene on a yeast artificial chromosome (YAC) were assessed at age 4 and 21 months, and APPSwe/PS1dE9 miceco-expressingmutant amyloid precursor protein (APPSwe) and presenilin-1 (PS1dE9) were assessed at age 4 and 9 months. Significantly increased (1.4-fold) GFAP expression was observed in APPSwe YAC c.f. wild-type (Wt) mice aged 21 months, when Aβ deposition was first evident in these mice. InAPPSwe/PS1dE9 mice aged 4 and 9 months, GFAP expressionwas significantly increased(1.6- and 3.1-fold, respectively)c.f. Wt mice,and wasassociated with robust Aβ depositionat 9 months.BDNF expression was significantly lower in4 and 21 month-old APPSwe YAC mice (0.8- and 0.6-fold, respectively)c.f. age-matched Wt mice, whereasproBDNF expression was significantly higher (10-fold) in the APPSwe YACc.f. Wt mice aged...
Source: Clinical and Experimental Pharmacology and Physiology - Category: Drugs & Pharmacology Authors: Tags: Clin Exp Pharmacol Physiol Source Type: research